Home Depot Inc vs McKesson Corporation — how do they compare? Home Depot Inc trades at $295.98 (market cap $285.11B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: Home Depot Inc is far larger — about 2.7× McKesson Corporation's market cap, and Home Depot Inc pays the higher dividend (3.26%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and McKesson Corporation for 74 Days on average.
| HD | MCK | |
|---|---|---|
Market Cap | $285.11B | $106.14B |
Volume | 5,334,053 | 794,405 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $995.69 |
52-Week Low | $281.15 | $725.17 |
Typical Hold Time | 139 Days | 74 Days |
Enterprise Value | $345.59B | $112.67B |
Dividend Yield | 3.26% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $295.47, up 3.06% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $159.51B in 2025, with net income of $14.81B and a net margin of 8.41%. Recent quarterly earnings have consistently beaten expectations, including Q2 2026 EPS of $4.92 versus $4.73 expected. Cash flow from operations remains strong at $19.81B in 2025, though net cash flow was negative due to significant investing outlays. The stock is near its 52-week low, with key support at $282.
The outlook for HD is mixed; strong Pro segment demand and housing tailwinds support long-term growth, but near-term headwinds include weak big-ticket demand and margin pressure. Analyst consensus is bullish with a $379.93 price target, yet rising mortgage rates and competitive pressures pose risks. Investment appeal hinges on execution in a challenging housing market.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →